inference, it is possible to establish which treatment is superior, reaching, through indirect comparison, reliable conclusions otherwise impossible to achieve. The primary objective of this study was therefore to determine whether anaesthetic techniques (TIVA vs volatile-based anaesthesia) confer a survival advantage for patients undergoing cardiac surgery. A secondary aim was to explore whether a particular volatile (desflurane, isoflurane, or sevoflurane) or TIVA (propofol) agent is associated with improved survival.
Methods
To address the question whether the choice of the anaesthetic might influence patients' survival after cardiac surgery, we carried out standard meta-analyses and Bayesian network meta-analyses to compare the effect on mortality of desflurane, isoflurane, sevoflurane, and TIVA.
When head-to-head treatment comparisons are not available or conclusive, network meta-analyses can provide estimates of treatment efficacy of multiple treatment regimens. Different treatments are analysed by statistical inference, rather than simply summing up trials that evaluated the same drug management compared with control, so that the results come from combining both direct and indirect estimates. To model the binomial data, we applied the Bayesian hierarchical model using Markov Chain Monte Carlo (MCMC) approaches.
Search strategy and study selection
Pertinent studies were independently searched in BioMedCentral, MEDLINE/PubMed, Embase, and the Cochrane Central Register of clinical trials by two expert investigators. Literature searches were last updated on June 1, 2012. The full PubMed search strategy was developed according to BiondiZoccai and colleagues 12 and is available in the Appendix.
Further hand or computerized searches involved the recent (2010 -2012) conference proceedings from the International Anaesthesia Research Society, American Heart Association, American College of Cardiology, American Society of Anesthesiologists, and European Society of Cardiology congresses.
Study selection
References obtained from database, literature searches with cross-check of references, experts, and manufacturers were first independently examined at a title/abstract level by two investigators and then, if potentially pertinent, retrieved as complete articles. No language restriction was imposed and non-English articles were translated and included in the analyses. The following inclusion criteria were used for potentially relevant studies: random allocation to treatment and comparison between a TIVA and an anaesthesia plan including administration of isoflurane, desflurane, or sevoflurane or a comparison between volatile agents, performed in cardiac surgical patients with no restriction in dose and time of administration. The exclusion criteria were duplicate publications (in this case, the article reporting the longest follow-up was abstracted), non-human experimental studies, and lack of outcome data. Studies in which epidural analgesia/anaesthesia was given to all patients were included. 13 14 Studies in which ischaemic pre-conditioning or remote ischaemic pre-conditioning were performed in all patients were excluded because ischaemic preconditioning has pathways of cardiac protection that are similar to those of volatile anaesthetics 15 16 even if the cardiac protective properties of volatile agents are not limited to pre-conditioning. Two investigators independently assessed compliance to selection criteria and selected studies for the final analysis, with divergences finally resolved by consensus.
Data abstraction and study characteristics
Year of publication, setting, number of patients, volatile agent, anaesthetic comparator, and length of follow-up were collected (Table 1) together with baseline (age, diabetes, ejection fraction, chronic obstructive pulmonary disease, use of beta-blockers, and management of sulfonylurea, theophylline, or allopurinol) (Supplementary Table S1 ) and procedural (cardioplegia, time of cross-clamping, and number of coronary artery grafts) (Supplementary Table S2 ) data. Furthermore, we extracted and pooled data on mechanical ventilation, intensive care unit (ICU) stay, hospital stay, troponin I (ng ml
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), myocardial infarction (as per author definition), and use of inotropic agent.
'Total Intravenous Anaesthesia' was defined as a group not receiving volatile agents. 'Propofol' was defined as a TIVA group receiving propofol as main hypnotic agent and not receiving volatile agents. 'Volatile' (desflurane, isoflurane, or desflurane) was defined as a group receiving a volatile agent (even if added on top of a TIVA regimen and irrespectively on time of administration).
The endpoint of the present systematic review and meta-analysis of randomized trials was to identify differences in mortality at the longest follow-up available between volatile agents and TIVA and to identify whether one or more anaesthetics were superior or inferior in terms of survival, using standard meta-analyses and Bayesian network meta-analyses. If we found that the study had missing or incomplete data on survival, we contacted all authors by letter, e-mail, or both.
The methodological details 17 -21 for the internal validity and risk of bias assessment, for the statistical analyses and for the details on the conduction of the Bayesian network meta-analyses are reported as Supplementary data. In summary, the internal validity was evaluated according to the Cochrane Collaboration methods; the overall risk of bias was expressed as low, moderate, or high; the evidence of publication bias was assessed by analytic appraisal based on both Peters' and Begg's test; the heterogeneity assumption among studies within direct contrast was evaluated by means of Cochran Q-test and by I 2 by Higgins and Thompson; 17 the validity and the symmetry of the entire Bayesian network meta-analysis was investigated visually by a graph of the network configuration. The presence of effect-modifiers attributable to heterogeneity was considered acceptable if the x 2 P-value was .0.10. Mortality data from individual studies Anaesthetic drugs and survival in cardiac surgery were analysed in order to compute pooled odds ratio (OR) with pertinent 95% confidence intervals (CIs), by means of the inverse variance method with the fixed effect model or the DerSimonian-Laird method with random effect model; the pairwise association between each treatment was delineated by a graphical representation of the network; the network analysis was carried out modelling the binary outcome mortality with the Bayesian hierarchical model (binomial model with logit link function) using the MCMC approach; the indirect estimate was calculated as the difference from the appropriate direct estimates and the corresponding 95% credibility intervals (CrI) was obtained by normal approximation; we selected the fixed or random effect model calculating the posterior mean of residual deviance (D res ) and the deviance information criterion (DIC) statistics.
To explore the association between log-risk of mortality and both the length of study follow-up and the year of publication, we performed meta-regression analyses using the Bayesian approach. Other sub-analyses on mortality outcome were performed analysing the three volatile agents (isoflurane, desflurane, and sevoflurane) separately, in studies using propofol as TIVA, in studies with .100 patients and stratifying by setting, such as overall coronary artery bypass graft (CABG) patients, off-pump or on-pump with cardiopulmonary bypass (CPB), and non-CABG surgery.
Sensitivity meta-analyses were performed by analysing data from studies with low risk of bias and by sequentially removing each study from the overall dataset. The statistical analysis was performed by STATA (release 11, College Station, TX, USA), winBUGS (release 1.4, freeware available by BUGS project), and SAS 2002-2008 program (release 9.2 by SAS Institute, Inc., Cary, NC, USA). Statistical significance was set at the two-tailed 0.05 level for hypothesis testing. Unadjusted P-values are reported throughout. This study was performed in compliance with the Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 20 Figure 1 shows the flow chart for the selection of randomized trials. Database searches, snowballing, and contacts with experts yielded a total of 2630 citations. Excluding 2518 non-pertinent titles or abstracts, we retrieved in complete form and assessed according to the selection criteria 112 studies. A total of 74 studies were further excluded because of their non-experimental design, including the use of historical controls, or because of duplicate publication. Specifically, we excluded 48 studies 1 -48 studies were performed in valve surgery patients (two aortic valve replacement and three mitral surgery). Baseline and procedural features were largely similar across the included studies. The most common pairwise comparison was sevoflurane vs propofol (11 studies) followed by isoflurane vs propofol (six studies) and desflurane vs propofol (six studies). Three-and four-arm studies represented altogether 16% of the trials. Studies appeared to be of medium quality. Particularly, 19 (50%) of the randomized controlled trials (RCTs) were regarded to have low risk of bias, while the other studies lacked important details on the method used for random sequence generation and allocation (Supplementary Table S3 ). Many studies did not have blinding of the anaesthesiologists but of the staff collecting the outcome data.
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Results
Description of included trials
Quantitative data synthesis
The overall standard meta-analysis (Fig. 2) showed that the use of volatile agents (isoflurane, desflurane, or sevoflurane) was Fig. S1 ). Nonetheless, as quantitative evaluation suggested a possible presence of publication bias, as measured by Peters' test (P¼0.02) and Begg's test (P¼0.18), we used the trim-and-fill approach (adding the missing studies as suggested by the computer) to confirm the results of our meta-analysis after adjusting for the theoretical presence of unpublished studies (OR¼0.43, 95% CI 0.28 -0.64, P-value for effect ,0.001, P-value for heterogeneity¼0.9, I 2 ¼0%, with 13 studies added).
The results of secondary and sensitivity analysis are reported in Table 2 . Volatile agents were associated with a reduced time of mechanical ventilation, and duration of ICU and hospital stay. Furthermore, of 17 studies with troponin I analysis, 7 significantly favoured the volatile regimen, in 6 we observe a trend in favour of volatile agents and in 4 a trend in favour of TIVA.
When comparing TIVA, isoflurane, desflurane, and sevoflurane through direct comparisons, we found non-significant differences in mortality: (i) isoflurane [3/ The similarity assumption, within each contrast, was confirmed by I 2 ,25%. The network configuration of each contrast analysed by a Bayesian network meta-analysis is reported in Figure 3 . As the fixed (D res ¼127.5 and DIC¼149.4 at the longest follow-up available; D res ¼111.5 and DIC¼131.4 at short-time mortality) and random (D res ¼126.5 and DIC¼150.1 at the longest follow-up available; D res ¼110.8 and DIC¼132.0 at short-time mortality) effects models were indistinguishable in terms of model fit, we selected the first that estimated the effect by slightly increasing the precision.
The final results are reported in Table 3 . We calculated the indirect estimate as difference from the appropriate direct estimates (probability in favour of inconsistency model equal to 0.03 and to 0.05 at the longest follow-up available and at shorttime mortality, respectively) and calculated the indirect 95% CrI by normal approximation. The Bayesian network meta-analysis ( 0.14 -0.64) and desflurane (posterior mean of OR¼0.43, 95% CrI 0.21-0.82) were associated with a reduction in mortality when compared with TIVA at the longest follow-up available. When the De Hert study 18 was removed, we found that only the use of desflurane was associated with a significant reduction in mortality with respect to TIVA (posterior mean of OR¼0.30, 95% CrI 0.09-0.88). When the Bayesian network meta-analysis was repeated, including all studies using propofol, we found a significant treatment difference effect between sevoflurane and propofol (posterior mean of OR¼0.37, 95% CrI 0.13 -0.98). Furthermore, Bayesian meta-regressions of the average follow-up against log-risk of mortality showed no significant effect for time on mortality (regression coefficient¼ 20.0008, CrI 20.004 to 0.002 and regression coefficient¼ 20.019, CrI 20.060 to 0.003, including all studies using TIVA or propofol, respectively). The Bayesian meta-regressions of average of the year of publication against mortality log-risk showed no significant effect when including all studies using TIVA (regression coefficient¼ 20.058, CrI 20.048 to 0.185) and a significant association when analysing only those studies using propofol (regression coefficient¼0.259, CrI 0.007 -0.545): adjusting for the effect of year of publication, we observed a more intense difference effect between sevoflurane and propofol (posterior mean of OR¼0.30, 95% CrI 0.10 -0.86).
When repeating all the Bayesian network meta-analyses using short-term mortality (≤30 days after surgery) as an endpoint, we found only a trend towards a reduction in mortality when comparing desflurane vs TIVA (posterior mean of OR¼0.41, 95% CrI 0.15-1.04).
Supplementary Table S4 reports, for each anaesthetic agent, the posterior distribution of the probability to be the best and the worst, showing a trend of both TIVA and propofol to be the worst in terms of the long-and short-term survival after cardiac surgery. 
Discussion
Our principal findings
This meta-analysis has several important findings. First of all, volatile agents (isoflurane, desflurane, and sevoflurane) seem to reduce mortality after cardiac surgery when compared with TIVA. Mortality at the longest follow-up available was doubled in patients receiving TIVA compared with patients receiving volatile agents [25/1994 (1.3%) in the volatile group vs 43/1648 (2.6%) in the TIVA arm P¼0.004], with 35 studies included and no statistical heterogeneity. Secondly, even if each volatile agent showed approximately a 50% reduction in mortality when compared with TIVA [desflurane (1.8 vs 4.0%), isoflurane (0.7 vs 2.0%), and sevoflurane (1.2 vs 3.0%)], none of these analyses was statistically significant per se, possibly because of the relatively limited number of patients enrolled (953, 1451, and 1698, respectively); we were therefore able to identify a benefit in survival only aggregating the three volatile agents together. Thirdly, few direct comparisons between the three volatile agents exist (nine overall). Even performing a Bayesian network meta-analysis with direct and indirect comparisons using the TIVA group as comparator, we were unable to identify whether there is a best or a worst volatile agent according to survival. Finally, our Bayesian network meta-analyses show that conducting cardiac anaesthesia with TIVA, including propofol-based TIVA, seems to increase mortality, especially when the comparator is desflurane or sevoflurane.
Strengths of our study in relation to other studies
The findings of the present Bayesian network meta-analysis confirm those of previous studies suggesting that the beneficial effects of volatile agents could translate into a reduction in mortality, but add relevant new data and provide methodologically innovative and more robust pieces of information. A first meta-analysis 3 suggested that desflurane and sevoflurane were associated with a reduced mortality in cardiac surgery when compared with TIVA, but it included only half as many patients and studies, used less robust analyses, did not include isoflurane in the analyses, and had no direct and indirect comparisons between agents. Similar considerations apply to a more recent 8 meta-analysis performed on isoflurane only and showing a trend (P¼0.05) towards a reduction in mortality in a subgroup of high-quality studies comparing isoflurane vs propofol in cardiac surgery. A relatively small RCT 6 reported large 1 yr mortality differences between sevoflurane, desflurane, and TIVA in CABG patients but a disproportionately high mortality rate was reported in the TIVA group. In accordance with our results, a retrospective study 2 suggested a beneficial effect on survival with the use of sevoflurane in low-risk CABG surgery. Finally, a meta-regression of .34 000 cardiac surgery procedures done in Italy 4 suggested that isoflurane was the most effective volatile agent to reduce mortality in cardiac surgery; these findings are only in part contradicted by our results, suggesting that desflurane and sevoflurane are associated with a more obvious survival benefit. Both analyses are probably driven by the high number of patients receiving isoflurane in the meta-regression and by the high number of patients receiving desflurane and sevoflurane in our analyses.
Weaknesses of our study
Several limitations are acknowledged. Most of the studies included in this meta-analysis were single-centred, and thus exposed to more bias. 28 Furthermore, double blindness could not be expected in the setting of anaesthesia for cardiac surgery because of safety reasons. We also excluded studies using ischaemic pre-conditioning or remote ischaemic preconditioning without investigating synergist or antagonist effects. The specific limitations of Bayesian network meta-analyses 18 29 -31 are detailed in the Supplementary data. Traditional limitations of meta-analyses attributable to variations in the treatment regimens, in populations or major subgroups within trials, and in the conduct of the trials also apply to this Bayesian network meta-analysis. In particular, we noted that after the removal of the largest trial 18 from the meta-analysis, only the use of desflurane was still associated with a significant reduction in mortality compared with TIVA-this means that the number of patients enrolled in this setting is still low and increases the need for a large randomized controlled trial. In fact, the overall results of this meta-analysis are still statistically fragile as there were only 68 deaths and statistical significance is reached only when combining all volatile agents and comparing them with TIVA. Anaesthetic drugs and survival in cardiac surgery BJA Nonetheless, it should be acknowledged that we have included all the randomized studies ever done in cardiac surgery that included mortality data (38 studies with 3966 patients) and therefore there is no possibility to have 'more evidence' than that provided in this manuscript. Interestingly, the effect sizes of the three volatile agents are comparable in magnitude (OR¼0.71 for isoflurane, OR¼0.64 for desflurane, and OR¼0.80 for sevoflurane). It should also be acknowledged that the magnitude of effect is large (absolute reduction of 1% or relative reduction of 50% in mortality) and that any systematic review, even a network meta-analysis, may overly depend on one or a few trials with very extreme findings such as the large De Hert paper that accounts for almost half of the overall deaths ( Supplementary Fig. S2) ; however, inclusion of so many trials, patients and events, and use of random effects methods may largely safeguard us from Type I and II errors. Furthermore, even if the cardiac protective properties of volatile agents reduce mortality in patients undergoing cardiac surgery, it cannot be excluded that they have significant positive or detrimental effects on other organs such as the brain.
Interpretation and implications of our findings
Our Bayesian network meta-analysis strongly supports the hypothesis that volatile anaesthetics may be superior to a TIVA-based anaesthesia according to a major postoperative outcome such as all-cause mortality. Experimental data suggest that direct positive effects of volatile anaesthetics may be because of specific cardioprotective properties, including, at least in part, pre-conditioning and post-conditioning mechanisms, which attenuate apoptosis and necrosis, and reduce myocardial dysfunction after ischaemia and reperfusion. Cardiac protection may be mediated by early activation of protective enzymes in the signalling pathways and late induction of the synthesis of protective proteins in the heart. 32 33 Coronary vasodilation, 34 and anti-inflammatory/antioxidant 35 36 activities of inhalation agents may play a role in this protection. Such a protective mechanism may extend to different degrees to other organ systems. 37 -41 Moreover, the contribution of inhalation agents to preserving cardiac function and satisfactory haemodynamics may ensure adequate perfusion and oxygenation of other organ systems and improve the chances for an uneventful recovery after surgery. All these effects can well expand beyond the immediate perioperative period and impact on long-term survival because of different modalities. We may speculate on a prolonged active protection of volatile anaesthetics because of their effects on cellular genomic expression. More simply, potential myocardiocyte-sparing effect of volatile anaesthetics during surgery means that more myocardium may be preserved and viable in the early and late postoperative periods, and potential reduced perioperative myocardial dysfunction may have implications on early and late function of other organ systems. The combination of these effects can well expand beyond the immediate perioperative period.
Our Bayesian network meta-analysis cannot exclude whether volatile agents could be simply less detrimental to mortality than TIVA in these settings. Nevertheless, propofol has been shown to modulate various inflammatory responses in experimental studies, 42 43 with a potential role in critically ill patients requiring additional studies to be validated. Whether the effects of inhalation agents on mortality in cardiac surgery are attributable to a positive protection or to a less detrimental effect than propofol, the choice of inhalation anaesthesia could still have a great impact on a large scale. If all anaesthetics are detrimental and volatile agents are simply less detrimental than TIVA, we should do our best to identify new agents with even less detrimental effects. Conversely assuming a positive protection by inhalation agents could 44 it is unlikely that these results will be clinically relevant 11 73 as it is difficult to anticipate adverse cardiac events in non-cardiac surgery.
Conclusions
Volatile anaesthetics improve survival in cardiac surgery when compared with TIVA. No clear data exist to suggest that one volatile agent (isoflurane, desflurane, or sevoflurane) is more beneficial than others, but there is preliminary evidence to suggest that TIVA is detrimental when compared with desflurane and sevoflurane. Cardiac anaesthesiologists, cardiac surgeons, and perfusionists should be aware that anaesthetics have pharmacological properties that go beyond the pharmacodynamic or pharmacokinetic properties and that the anaesthetic plan should take into account the effect of these drugs on survival. As the evidence comes from small trials, it is imperative to conduct a large, multicentre trial to confirm that 1 yr survival is significantly influenced by the choice of the anaesthetic.
